ThromboGenics and BioInvent Announce Alliance with Roche

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gary Steinberg, MD

September 29th 2025

Older matched sibling donor versus young haplo-identical donor for elderly patients with acute myeloid leukemia

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

American Society for Transplantation and Cellular Therapy

Diving Into the Practical Applications of ctDNA in Oncology Care

Researchers conducted a large registry-based analysis comparing haploidentical donors and older matched sibling donors in older patients with AML.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP

September 25th 2025

Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

American Society for Transplantation and Cellular Therapy

Radiation Shows Similar 10-Year Outcomes Vs Surgery in Early-Stage NSCLC

Why do some patients with follicular lymphoma experience benefit from axi-cel while others relapse or develop severe toxicities?

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.

Russ Conroy

Proton Vs Photon Therapy Yields Similar HRQOL in Non-Metastatic Breast Cancer

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.

Related Content

Ariana Pelosci

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.

Gary Steinberg, MD

September 29th 2025

Older matched sibling donor versus young haplo-identical donor for elderly patients with acute myeloid leukemia

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

American Society for Transplantation and Cellular Therapy

Diving Into the Practical Applications of ctDNA in Oncology Care

Researchers conducted a large registry-based analysis comparing haploidentical donors and older matched sibling donors in older patients with AML.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP

September 25th 2025

Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

American Society for Transplantation and Cellular Therapy

Radiation Shows Similar 10-Year Outcomes Vs Surgery in Early-Stage NSCLC

Why do some patients with follicular lymphoma experience benefit from axi-cel while others relapse or develop severe toxicities?

Russ Conroy